期 |
标题 |
文件 |
卷 2, 编号 1 (2020) |
Approaches to the assessment of quantitative composition of drugs based on natural peptides containing glycosaminoglycan-peptide complex |
(Rus)
|
Vengerovich N., Efimov N., Rogozhina N., Stepchenkov V.
|
卷 2, 编号 1 (2020) |
Evaluation of the 223Ra-dichloride biodistribution models for the assessment of the doses from internal exposure |
(Rus)
|
Vodovatov A., Chipiga L., Petrova A., Stanzhevsky A.
|
卷 2, 编号 1 (2020) |
Aspects of pesticide and agrochemical application in the field of beekeeping |
(Rus)
|
Paramonov S.
|
卷 2, 编号 1 (2020) |
Valery Galynkin: "a Scientist should also be a practitioner» |
(Rus)
|
Zvyagin Y.
|
卷 2, 编号 1 (2020) |
Moses Efimovich Bergolts: first rector of the revived institute |
(Rus)
|
Narkevich I., Stepanov S., Zvyagin Y., Vorobeva S., Perelygin V., Dobrova D.
|
卷 2, 编号 1 (2020) |
Modern polymers in prolonged release tablet technology |
(Rus)
|
Kotsur J., Flisyuk E.
|
卷 2, 编号 1 (2020) |
Morpholine derivatives as potential agents for neurological manifestations of nervous system diseases |
(Rus)
|
Prikhodko V., Sysoev Y., Okovityi S.
|
卷 2, 编号 1 (2020) |
Pathogenic substantiation of application of erythropoietin modified forms and peptide analogues as cytotprotectors |
(Rus)
|
Ivanov I., Nikiforov A., Vengerovich N., Perelygin V., Proshina Y.
|
卷 2, 编号 1 (2020) |
Processing and evaluation of qualitative data of the pharmaceutical market using economic and statistical methods |
(Rus)
|
Umarov S.
|
卷 2, 编号 1 (2020) |
From the editors |
(Rus)
|
Narkevich I.
|
卷 2, 编号 4 (2020) |
Approaches to assessing the sexual behavior of male rats in the study of the effects of compounds that have a stimulating effect on sexual function |
(Rus)
|
Subbotina S., Kryazhevskikh A., Kryazhevskikh A., Yudin M., Eletskaya E.
|
卷 3, 编号 1 (2021) |
The development of an algorithm for introduction of a new drug on the existing pharmaceutical production. Stage 2. Transfer of technologies |
(Rus)
|
Basevich A., Dzjuba A., Kaukhova I., Tretyakova A., Sakharov V.
|
卷 2, 编号 4 (2020) |
Multi-vector analysis of the market for drugs used to treat hepatitis C |
(Rus)
|
Narkevich I., Nemyatykh O., Siukaeva D., Tsitlionok E., Lisacenco V., Grinyuk A.
|
卷 2, 编号 4 (2020) |
The aspects that describe the pre-clinical studies of aceclofenac, as an instrument of registration of a generic drug |
(Rus)
|
Anisimova N., Selizarova N., Plisko G., Semivelichenko E., Napalkova S.
|
卷 2, 编号 4 (2020) |
Generalized data of criteria of risk factors for the use of the drug torasemide from the materials of its preclinical studies |
(Rus)
|
Anisimova N., Selizarova N., Plisko G., Semivelichenko E., Napalkova S.
|
卷 2, 编号 4 (2020) |
Identification of actoprotective compounds among Krebs cycle acid/aminoethanol derivatives |
(Rus)
|
Bolotova V., Shustov E., Okovityi S.
|
卷 2, 编号 4 (2020) |
The benefits or harms of systemic corticosteroids for community-acquired pneumonia in adults: аn overview of reviews |
(Rus)
|
Efimov N., Sayfullin R., Shunkov V.
|
卷 2, 编号 4 (2020) |
Modern aspects of myocardial infarction treatment in older patients |
(Eng)
|
Kozlov K., Bogomolov A., Lukianov N., Senkina E., Pukhalskaya A.
|
卷 2, 编号 4 (2020) |
Development of the design of the preclinical trials of radiopharmaceuticals for the radionuclide diagnostics and therapy based on the AMBA peptide |
(Rus)
|
Stanzhevsky A., Mosunov A., Chipiga L., Vodovatov A., Naurzbaeva L., Kushnarenko S., Lavreshov D., Petrova A.
|
卷 2, 编号 4 (2020) |
Search for the optimal mass profile of neuropeptides for the implementation of antihypoxic and activating actions |
(Rus)
|
Shustov E., Ivkin D., Ivkina A., Kim A., Lublin S., Nesterov M.
|
卷 2, 编号 4 (2020) |
Prevention and treatment of cancer using so-called medicinal mushrooms raw materials: Criticism, facts, and perspectives |
(Rus)
|
Zmitrovich I., Vlasenko V., Perelygin V., Figurin I.
|
卷 3, 编号 1 (2021) |
Dementia in elderly patients as a consequence of arterial hypertension: a literature review |
(Rus)
|
Mikhailov S., Kozlov K., Shishkevich A., Bessonov E., Lukjanov N., Pukhalskaya A.
|
卷 2, 编号 4 (2020) |
Antipsychotics: from first to third generation |
(Rus)
|
Petrova N., Sofronov A.
|
卷 2, 编号 4 (2020) |
From the editorial Board |
(Rus)
|
Perelygin V., Zvyagin Y.
|
卷 2, 编号 4 (2020) |
Adel Fedorovna Hammermann (1888–1978) |
(Rus)
|
Narkevich I., Luganin V., Bespalova N., Zvyagin Y., Perelygin V.
|
卷 2, 编号 4 (2020) |
Investigation of the antibacterial effectiveness of drinking water preparation using the “TYENT Water Ionizer” |
(Rus)
|
Paramonov S.
|
卷 2, 编号 4 (2020) |
“Young pharmacy-the potential of the future” 2020: result of conference |
(Rus)
|
Zagorulko E., Rozhkov G., Povydysh M.
|
卷 2, 编号 4 (2020) |
Ensuring energy efficiency at pharmaceutical enterprises in the paradigm of reducing the technogenic load on the environment |
(Rus)
|
Perelygin V., Sklyarova N., Miroshnichenko Y., Ivanov S., Sakharov V., Drachkova I., Zharikov M.
|
卷 2, 编号 4 (2020) |
Unique archive of medical history scientific materials are already available! |
|
扎里科夫 迈.
|
卷 3, 编号 1 (2021) |
Pyotr Ivanovich Astrakhantsev: the first post-war director of the Leningrad Institute of Pharmacy |
(Rus)
|
Narkevich I., Stepanov S., Volgusheva A., Zvyagin Y., Vorobeva S., Perelygin V.
|
卷 3, 编号 1 (2021) |
The role of scientists in the Department of Psychiatry at the S.M. Kirov Military Medical Academy in the development of domestic narcology and pharmacological methods of treating this pathology |
(Rus)
|
Tchudinovskih A., Zvyagin Y.
|
卷 3, 编号 1 (2021) |
Docking of highly selective 5-HT2A/C receptor peptide ligands with antipsychotic activity |
(Eng)
|
Orlova A., Sventitskaya A., Vengerovich N., Nikiforov A., Ivanov I., Proshina Y.
|
卷 3, 编号 1 (2021) |
Medical gas supply systems in the context of a pandemic |
(Rus)
|
Kravchenko A.
|
卷 3, 编号 1 (2021) |
Comparative bioelectronic diagnostics of the ecological state of contaminated water areas (on the example of some ducts of the Volga River Delta) |
(Rus)
|
Kholodkevich S., Motruk M., Lyubimtsev V., Susloparova O.
|
卷 3, 编号 1 (2021) |
From the editor |
(Rus)
|
Narkevich I., Perelygin V.
|
卷 3, 编号 1 (2021) |
Comparison of the therapeutic effectiveness of the drug Mucosat based on glycosaminoglycans in oral and parenteral dosage forms in the treatment of osteoarthritis |
(Rus)
|
Peshekhonova L., Peshekhonov D., Pyatibrat A., Vengerovich N.
|
卷 3, 编号 1 (2021) |
The significance of the original characteristics of the active substance of injectable chondroitin sulfate preparations for intramuscular injections in the evidence-based medicine |
(Rus)
|
Napalkova S., Okovityi S., Ivkin D., Pyatibrat A.
|
卷 3, 编号 2 (2021) |
Battery of tests for studying the adaptogenic effects of biologically active substances in preclinical trials |
(Rus)
|
Shustov E., Okovityi S., Bolotova V., Kim A.
|
卷 3, 编号 2 (2021) |
Tumor growth – a modern view of pathogenesis and pharmacotherapy (lecture) |
(Rus)
|
Tyukavin A., Suchkov S.
|
卷 3, 编号 2 (2021) |
Regulatory framework and prospects for the implementation of the Electronic Prescription System in the Russian Federation |
(Rus)
|
Zolotareva N., Pokhvalenko E.
|
卷 3, 编号 2 (2021) |
Some aspects of pesticide contamination of medicinal plants |
(Rus)
|
Paramonov S.
|
卷 3, 编号 2 (2021) |
Socio-biological factors of increased morbidity risk in participants of educational process in higher education institutions related to the global epidemiological situation in 2020-2021 |
(Rus)
|
Perelygin V., Paramonov S., Sklyarova N., 扎里科夫 迈., Sklyarova L.
|
卷 3, 编号 2 (2021) |
Director Nikolai Vasilyevich Koshkin: the Institute has become Chemical and Pharmaceutical again |
(Rus)
|
Narkevich I., Stepanov S., Volgusheva A., Zvyagin Y., Vorobeva S., Perelygin V.
|
卷 3, 编号 2 (2021) |
State of the Russian Oncology Service: malignant neoplasms of the tongue C01, 02 (age-specific incidence rate, localization and histological structure) Part 1 |
(Eng)
|
Merabishvili V., Merabishvili E., Shcherbakov A., Vasilyev A., Barsukov A., Krotov N.
|
卷 3, 编号 2 (2021) |
State of the Russian Oncology Service: malignant neoplasms of the tongue C01, 02 (mortality rate and median survival of patients, taking into account the stage of the disease and histological structure of the tumor) Part 2 |
(Eng)
|
Merabishvili V.M., Merabishvili E., Scherbakov A., Vasilyev A., Krotov N., Barsukov A.
|
卷 3, 编号 2 (2021) |
Foreign experience in veterinaryapplication of scintigraphy |
(Rus)
|
Lunegova I., Tyts V., Lunegov A.
|
卷 3, 编号 2 (2021) |
Steroid hormones and their metabolites in water of centralized drinking water supply systems as ecopolutants |
(Rus)
|
Vengerovich N., Perelygin V.
|
卷 3, 编号 2 (2021) |
Personal protective equipment waste potentially infected with SARS-CoV-2 – a new global challenge for biological safety |
(Rus)
|
Donchenko V., Sakharov V., Sakharova O.
|
卷 3, 编号 1S (2021): Supplement |
From the editor |
(Rus)
|
Perelygin V.
|
卷 3, 编号 1S (2021): Supplement |
Opening remarks |
(Rus)
|
Flisyuk E.
|
卷 3, 编号 1S (2021): Supplement |
Opening remarks |
(Rus)
|
Donchenko V.
|
卷 3, 编号 1S (2021): Supplement |
Approaches to training and supply of qualified personnel for radiation medicine facilities |
(Rus)
|
Perelygin V., Sklyarova N., Sakharov V., Zharikov m.
|
卷 3, 编号 1S (2021): Supplement |
Methods of biological waste management generated by patients |
(Rus)
|
Vodovatov A.
|
卷 3, 编号 1S (2021): Supplement |
Review of the practice-based experience of radiopharmaceutical waste management in healthcare institutions |
(Rus)
|
Donchenko V., Sakharov V., Sakharova O.
|
卷 3, 编号 1S (2021): Supplement |
Epidemiology and survival rates of patients with malignant tumors in the Russian Federation |
(Rus)
|
Merabishvili V.
|
卷 3, 编号 1S (2021): Supplement |
Prospective directions and problems of ensuring Radiation Safety in Radiation Medicine |
(Rus)
|
Chipiga L.
|
卷 3, 编号 1S (2021): Supplement |
Radiation Medicine: Past and Present |
(Rus)
|
Soukhov V.
|
卷 3, 编号 1S (2021): Supplement |
Practical experience in reactor and cyclotron radiopharmaceuticals production at the V.G. Khlopin Radium Institute |
(Rus)
|
Kudellin B.
|
卷 3, 编号 1S (2021): Supplement |
Quality control management in the production of radiopharmaceuticals at the A.M. Granov Russian Scientific Centre for Radiology and Surgical Technologies |
(Rus)
|
Nepochatov I.
|
卷 3, 编号 1S (2021): Supplement |
Science research experience in the use of radiopharmaceuticals at the N.N. Petrov NMRC of Oncology |
(Rus)
|
Krzhivitsky P.
|
卷 3, 编号 1S (2021): Supplement |
FATTY LIVER DYSTROPHY MODELING BY USING STRONTIUM SULFATE |
(Rus)
|
Ponamarev V., Lunegov A., Lunegova I., Baryshev V., Zenkov K.
|
卷 3, 编号 1S (2021): Supplement |
PRELIMINARY RISK ANALYSIS METHOD FOR POTENTIAL CAUSES OF MEDICAL DEVICE FAILURE WITH THE USE OF DEDUCTIVE LOGIC IN CASE OF A MAN-MADE EMERGENCY SITUATION |
(Rus)
|
Babkin I.
|
卷 3, 编号 1S (2021): Supplement |
Development of the environmentally safe habitat based on local life-support systems |
(Rus)
|
Leschinsky V.
|
卷 3, 编号 1S (2021): Supplement |
Ecotecture of the extreme Arctic environment |
(Rus)
|
Troshin V., Zvyagin Y.
|
卷 3, 编号 1S (2021): Supplement |
ACUTE RADIATION INJURY: COURSE AND OUTCOME IN A RAT MODEL WITH THE IODINE AND SELENIUM PREPARATIONS ADMINISTRATION |
(Rus)
|
Vasil'ev R., Troshin E., Brevnova S., Yugatova N.
|
卷 3, 编号 1S (2021): Supplement |
Greeting |
(Rus)
|
Narkevich I.
|
卷 3, 编号 1S (2021): Supplement |
Greeting |
(Rus)
|
Belyaev A.
|
卷 3, 编号 1S (2021): Supplement |
Greeting |
(Rus)
|
Mkrtchyan M.
|
卷 3, 编号 1S (2021): Supplement |
Greeting |
(Rus)
|
Archipenko L.
|
卷 3, 编号 1S (2021): Supplement |
Application of the Environmental Safety terms and definitions in pharmaceutical organizations |
(Rus)
|
Shmarova A.
|
卷 3, 编号 1S (2021): Supplement |
The decision of the scientific and practical conference " Environmental Protection. Assessment of environmental risks in the handling of radiopharmaceutical drug waste" |
(Rus)
|
Flisyuk E.
|
卷 3, 编号 2 (2021) |
Effect of organophosphorus compounds on the external respiratory functionin rats during intratracheal andintraperitonealadministration |
(Rus)
|
Kryazhevskikh A., Kryazhevskikh A., Subbotina S., Sklyarova N.
|
卷 3, 编号 3 (2021) |
State of the Russian Oncology Service: esophageal cancer. Population-based study at the federal district level. Part I. Morbidity and mortality rates, accuracy index, annual mortality |
(Eng)
|
Merabishvili V.
|
卷 3, 编号 3 (2021) |
State of the Russian Oncology Service: esophageal cancer. Population-based study at the federal district level. Part II. Median survival, observed and relative survival of patients considering disease stage and histological structure of tumors |
(Eng)
|
Merabishvili V.
|
卷 3, 编号 2 (2021) |
From the editor |
(Rus)
|
Perelygin V.
|
卷 3, 编号 3 (2021) |
Obtaining and research of pharmaceutical properties of antiemetics in a form of powder for inhalation |
(Eng)
|
Ivanov I., Pechurina T., Vengerovich N., Yudin M., Nikiforov A., Raguzin E., Kuzmich V., Proshina Y.
|
卷 3, 编号 3 (2021) |
Investigation of the properties and activity of DfCas9 and DsCas9 nucleases in eucaryotic cells |
(Rus)
|
Vlasova Y., Madera D., Gershovich P.
|
卷 3, 编号 3 (2021) |
Preliminary evaluation of patient radiation doses during radionuclide diagnostic with monoclonal antibodies labeled with 89Zr |
(Rus)
|
Chipiga L., Petrova A., Mosunov A., Naurzbaeva L., Kushnarenko S., Lavreshov D., Vodovatov A., Stanzhevsky A., Maistrenko D.
|
卷 3, 编号 2 (2021) |
CORRIGENDUM TO: [Pharmacy Formulas. - 2021. - Vol. 3. - N. 1. - P. 66-75. doi: 10.17816/phf60598] |
(Rus)
|
Peshekhonova L., Peshekhonov D., Pyatibrat A., Vengerovich N.
|
卷 3, 编号 3 (2021) |
Interactomics and personalized pharmacotherapy – present and looking to the future |
(Rus)
|
Tyukavin A., Studneva M., Suchkov S.
|
卷 3, 编号 3 (2021) |
Viktor Nikolaevich Ivanov: the Director of the Leningrad Institute of Chemistry and Pharmacy in the 1950s |
(Rus)
|
Narkevich I., Stepanov S., Zvyagin Y., Vorobeva S., Perelygin V.
|
卷 3, 编号 3 (2021) |
Development of professional standards in the area of medical and biological waste management for workers of 3-4 skill levels |
(Rus)
|
Perelygin V., Sklyarova N., Vasiliev V., Zharikov M., Sklyarova L.
|
卷 3, 编号 3 (2021) |
The role of society in public administration in the field of environmental protection. Global problems of our time. Part I |
(Rus)
|
Sapunov V., Zharikov M.
|
卷 3, 编号 4 (2021) |
Biodizine as a civilizational challenge of modern pharmaceuticals |
(Rus)
|
Tyukavin A., Arseniev N., Studneva M., Medvedeva V., Suchkov S.
|
卷 3, 编号 4 (2021) |
State of the Russian Oncology Service: lip cancer. Population-based study at the federal district level. Part I. Incidence rate, annual mortality rate, localization and histological structure |
(Rus)
|
Merabishvili V., Vasilyev A., Merabishvili E., Barsukov A.
|
卷 3, 编号 4 (2021) |
State of the Russian Oncology Service: lip cancer. Population-based study at the federal district level. Part II. Survival of patients, median of survival, survival of patients taking into account the localization, histological
structure and disease stage |
(Rus)
|
Merabishvili V., Vasilyev A., Merabishvili E., Barsukov A.
|
卷 3, 编号 4 (2021) |
Applications of chitosan as a polymer carrier for increasing the drugs’ bioavailability |
(Rus)
|
Ustinova T., Vengerovich N., Glinko D.
|
卷 3, 编号 3 (2021) |
From the editor |
(Rus)
|
Efimov N.
|
卷 3, 编号 4 (2021) |
Supergroups of eukaryotes through a biotechnologist’s look. The system of eukaryotes and the need for a taxonomic/biotechnological interface |
(Rus)
|
Zmitrovich I., Perelygin V., Zharikov M.
|
卷 3, 编号 4 (2021) |
Information technologies in the analysis of pharmaceutical personnel security |
(Rus)
|
Klishchenko M., Kuznetsov D.
|
卷 3, 编号 4 (2021) |
The use of Mexidol-Vet® against the background of ultraviolet and gamma irradiation in rats |
(Rus)
|
Troshin E., Yugatova N., Vasil'ev R.
|
卷 3, 编号 4 (2021) |
Problems of solid radioactive waste management on the example of the radioactive isotope 14C |
(Rus)
|
Perelygin V., Kotenko P., Podboronova A., Zharikov M., Sklyarova L.
|
卷 3, 编号 4 (2021) |
Ecotoxicological assessment of waste and soil cover of anthropogenic polluted territories using biotest systems |
(Rus)
|
Bardina T., Podboronova A., Sklyarova L.
|
卷 3, 编号 4 (2021) |
Current issues in clinical trials of radiopharmaceutical drugs at the present stage of nuclear medicine development |
(Rus)
|
Efimov N., Lebedinets A.
|
卷 3, 编号 4 (2021) |
The formation of the SPSUVM Department of Pharmacology and Toxicology |
(Rus)
|
Lunegov A.
|
卷 4, 编号 1 (2022) |
Prevalence and survival of patients with malignant tumors of the thymus gland (C37) (population study at the federal district level) |
(Rus)
|
Merabishvili V.
|
卷 4, 编号 1 (2022) |
Environmental risks of the tetracycline micro pollution |
(Rus)
|
Paramonov S., Zelikova D., Sklyarova L., Alkhutova I.
|
卷 3, 编号 4 (2021) |
Development of the emulsion composition and technology based on iron oleate micelles |
(Rus)
|
Trofimov M., Goncharenko A., Plisko G., Semivelichenko E., Muslimov A., Ivkina A.
|
卷 3, 编号 4 (2021) |
A roadmap for the development of “Training system of specialists for nuclear medicine facilities at the Saint Petersburg State Chemical and Pharmaceutical University” |
(Rus)
|
Perelygin V., Sklyarova N.
|
卷 3, 编号 4 (2021) |
FROM THE EDITOR |
(Rus)
|
Narkevich I.
|
1 - 100 的 217 信息 |
1 2 3 > >> |